Trial Profile
Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of AZD9291 in Brain Metastases From Patients With EGFR T790M Positive NSCLC Who Have Received Prior Therapy With an EGFR-TKI
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms APOLLO study
- 17 Aug 2020 Status changed to completed, according to results published in the Clinical Cancer Research
- 17 Aug 2020 Results published in the Clinical Cancer Research
- 26 Sep 2018 Thirty-eight eligible patients were enrolled and 12 paired CSF-plasma samples were collected, according to results presented at the 19th World Conference on Lung Cancer.